9 top US children's hospitals use BioPorto's NGAL tests to assess AKI risk in pediatric patients.

BioPorto, a Danish in vitro diagnostics firm, revealed that nine of the ten best U.S. children's hospitals, according to U.S. News & World Report, utilize its Neutrophil Gelatinase-Associated Lipocalin (NGAL) tests. These tests assess Acute Kidney Injury (AKI) risk in critically ill pediatric patients. BioPorto's ProNephro AKI™ test, FDA-cleared for ages 3 months to 21 years, can detect kidney damage earlier than traditional methods, potentially improving patient outcomes.

October 22, 2024
5 Articles